Niagen Bioscience (NASDAQ:NAGE) vs. Unicharm (OTCMKTS:UNICY) Head to Head Review

Unicharm (OTCMKTS:UNICY) and Niagen Bioscience (NASDAQ:NAGE) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares Unicharm and Niagen Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicharm	6.65%	7.19%	5.28%
Niagen Bioscience	12.39%	17.95%	13.17%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Unicharm and Niagen Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicharm	0	2	0	0	2.00
Niagen Bioscience	0	1	3	1	3.00

Niagen Bioscience has a consensus price target of $10.33, suggesting a potential upside of 285.57%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Unicharm.

Risk and Volatility

Unicharm has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Valuation & Earnings

This table compares Unicharm and Niagen Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicharm	$6.32 billion	1.63	$436.93 million	$0.13	22.82
Niagen Bioscience	$129.08 million	1.65	$17.38 million	$0.18	14.89

Unicharm has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Unicharm, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.4% of Niagen Bioscience shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Niagen Bioscience beats Unicharm on 12 of the 15 factors compared between the two stocks.

About Unicharm

Unicharm Corporation engages in the manufacturing and sale of wellness, feminine, baby and children, kirei, and pet care products in Japan and internationally. The company's baby and child care products, including disposable diapers and wipes under the Moony, MamyPoko, Oyasumiman, and Torepanman brands; feminine care products comprise napkins, tampons, panty liners, sanitary short, panty liners, and other feminine care products under the Sofy, Center-In, and Unicharm brand names; and wellness care products include napkin-type incontinence pads, pants-type diapers, tape-type diapers, pants-type specialized urine pads, and tape-type specialized urine pads under the Lifree and Charmnap brand. It also provides masks under the Unicharm brand; home care products, including cleaning sheets under the Wave brand name; cosmetic cotton and wet wipes under the Silcot brand; and paper towels under the Cook Up brand name. In addition, the company offers pet care products that include pet foods, excrement cleanup sheets, system toilets, and disposable diapers under the Grand Deli, Best Balance, Physicalife Dog, Silver Plate, Aiken Genki, Manner Wear, Deo Sheet, Silver Spoon, AllWell, Physicalife Cat, Deo Toilet, Deo Sand, Deo Clean, and Neko Genki brands; and deodorizing beads. Further, it is involved in the manufacture and sale of industrial materials related products, etc., as well as food-packaging materials. Unicharm Corporation was incorporated in 1941 and is headquartered in Tokyo, Japan.

About Niagen Bioscience

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.